FDA Advisory Committee Discusses Clinical Data Package for BioMarin's Kyndrisa for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
November 24, 2015 at 19:36 PM EST
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Peripheral and Central Nervous System Drugs Advisory Committee of ...